Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 2Unknown 1

Sponsor Class

OTHER 6INDUSTRY 3NIH 2

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Breast 1

Conditions

Prostatic Neoplasms 2Breast Neoplasms 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Verteporfin × Clear all
NCT03067051 2026-05-01

Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System

SpectraCure AB

Phase 1/2 Recruiting
66 enrolled
Genitourinary

Prostatic Neoplasms

NCT06807359 2026-05-01

Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System

SpectraCure AB

Phase 1/2 Recruiting
43 enrolled
Genitourinary

Prostatic Neoplasms

NCT02939274 2018-07-20

An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer

Rogers Sciences Inc.

Phase 2 Unknown
15 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡